Who
Barbara Weber
Director
Company insider
Files Form 4 as: Director, Parabilis Medicines; Director, Executive Chair, Tango Therapeutics; Director, Revolution Medicines.
In numbers
- Trades disclosed
- 68
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $2.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 17 Jun 2020
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,215 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,215 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $370K30,186 at $12.26 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,295333 at $12.90 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $370K30,186 at $12.26 | filing |
| 3 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,296333 at $12.90 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,522 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —222,132 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —222,132 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,522 at $0.00 | filing |
| 5 Feb 2025filed 6 Feb 2025 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K9,013 at $3.16 | filing |
| 4 Feb 2025filed 6 Feb 2025 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Sold | $29K9,778 at $2.99 | filing |
| 3 Feb 2025filed 5 Feb 2025 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —635,250 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —105,875 at $0.00 | filing |
| 8 Oct 2024filed 10 Oct 2024 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Sold | $250K5,200 at $48.02 | filing |
| 21 Aug 2024filed 23 Aug 2024 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code D | $81K1,808 at $44.83 | filing |
| 20 Jun 2024filed 28 Jun 2024 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,955 at $0.00 | filing |
| 20 Jun 2024filed 28 Jun 2024 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —4,248 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —4,800 at $0.00 | filing |
News
Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?TNGX · insidermonkey.com · 20 Oct 2026Tango Therapeutics (NASDAQ:TNGX) Shares Up 7.5% – Should You Buy?TNGX · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Barbara Weber; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.